Dr. Gradishar on Selecting Agents for HER2+ Breast Cancer

William J. Gradishar, MD
Published: Friday, Aug 18, 2017



William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

HER2 breast cancer has seen the introduction of several new agents over the last decade.

One of the challenges, particularly in patients with metastatic disease, is how to optimally use these drugs to deliever the best benefit to the patient, says Gradishar.
 


William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine (Hematology and Oncology), Northwestern University Feinberg School of Medicine, discusses selecting agents for the treatment of patients with HER2-positive breast cancer.

HER2 breast cancer has seen the introduction of several new agents over the last decade.

One of the challenges, particularly in patients with metastatic disease, is how to optimally use these drugs to deliever the best benefit to the patient, says Gradishar.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x